Catalog No. |
TD-HV255056 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Human |
Isotype |
IgG4-kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
CD85 antigen-like family member D, Monocyte/macrophage immunoglobulin-like receptor 10, MIR-10, ILT4, LIR-2, ILT-4, Immunoglobulin-like transcript 4, MIR10, CD85d, Leukocyte immunoglobulin-like receptor subfamily B member 2, Leukocyte immunoglobulin-like receptor 2, LIR2, LILRB2 |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
Q8N423 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
CAS:2640981-19-5 |
Background |
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |